

HOTLINE: Effective August 16, 2021

---

**New Test**      **3004092**      **Edoxaban Level**      **EDOX**

**Methodology:** Chromogenic Assay  
**Performed:** Tuesday  
**Reported:** 1-8 days

**Specimen Required:** Collect: Lt. blue (sodium citrate). Refer to Specimen Handling at aruplab.com for hemostasis/thrombosis specimen handling guidelines.  
Specimen Preparation: Transport 2 mL platelet-poor plasma. (Min: 1 mL)  
Storage/Transport Temperature: CRITICAL FROZEN. Separate specimens must be submitted when additional tests are ordered.  
Remarks: This test cannot be used to quantitate anticoagulants other than Edoxaban. This includes but is not limited to Unfractionated Heparin, Low Molecular Weight Heparin, Apixaban (Eliquis), Rivaroxaban (Xarelto), and Fondaparinux (Arixtra).  
Unacceptable Conditions: Serum, EDTA, oxalate, heparin, or plasma separator tubes, hemolyzed specimens.  
Stability (collection to initiation of testing): After separation from cells: Ambient: 4 hours; Refrigerated: Unacceptable; Frozen: 1 month

**Reference Interval:** Not established

**Interpretive Data:**

When 60 mg edoxaban was administered daily for treatment of DVT and PE, edoxaban steady state levels were as follows:  
Peak: 149-317 ng/mL  
Trough: 10-39 ng/mL  
The lower limit of detection for this assay is 20 ng/mL.  
For additional information, please refer to [www.arupconsult.com](http://www.arupconsult.com)

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**CPT Code(s):** 80299

New York DOH approval pending. Call for status update.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.